Johnson & Johnson’s Janssen Biotech will codevelop Theravance’s TD-1473 and related backup compounds for inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease, the ...
DUBLIN, IRELAND--(Marketwired - Jun 9, 2016) - Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced positive results from the Company's Phase 1 clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results